Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients
Recruiting · NCT07524829 · Interventional (participants receive a specific treatment) · Lead sponsor: Azienda Sanitaria Locale di Asti
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy. Patients undergoing treatment with CDK inhibitors frequently experience adverse effects that may negatively impact treatment adherence, quality of life, and clinical outcomes. Early detection and timely management of these side effects are essential to optimize therapy and reduce complications, including unplanned hospitalizations and treatment interruptions. In this study, participants are randomly assigned to one of two groups: standard care or standard care plus a structured telenursing follow-up program. The intervention consists of scheduled remote contacts (telephone or video consultations) conducted by trained nursing staff at predefined time points during treatment. These contacts aim to monitor symptoms, provide education, reinforce adherence, and facilitate early identification and management of treatment-related toxicities. The primary objective of the study is to assess whether the telenursing intervention reduces the incidence and severity of treatment-related adverse events compared to standard care alone. Secondary objectives include evaluating its impact on emergency department visits, hospitalizations, treatment adherence, dose intensity, and patient-reported outcomes. The study is currently recruiting participants across multiple centers. Results from this trial may provide evidence to support the integration of structured telenursing programs into routine oncology care, with the potential to improve patient safety, treatment continuity, and overall clinical outcomes.
Who can take part
Inclusion criteria
- Female patients aged ≥18 years
- Histologically confirmed breast cancer
- Ongoing treatment with CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib)
- Ability to understand and provide informed consent
- Access to a telephone or digital communication device for telenursing follow-up
Exclusion criteria
- Inability to comply with the study procedures
- Cognitive impairment or psychiatric conditions interfering with participation
- Participation in another interventional clinical trial that may affect study outcomes
- Severe comorbidities limiting life expectancy or follow-up
Where it is running
1 location listed.
- Cardinal Massaia Hospital - S.C. Oncology, Azienda Sanitaria Locale AT (ASL AT) - Asti, ASTI, Italy